Aleix Prat

Servicio de Oncología Oncólogo

Publicaciones destacadas

  • Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Autores: Brasó-Maristany F., Griguolo G., Pascual T., Paré L., Nuciforo P., Llombart-Cussac A., Bermejo B., Oliveira M., Morales S., Martínez N., Vidal M., Adamo B., Martínez O., Pernas S., López R., Muñoz M., Chic N., Galván P., Garau I., Manso L., Alarcón J., Martínez E., Gregorio S., Gomis R.R., Villagrasa P., Cortés J., Ciruelos E., Prat A..
    Referencia: NATURE COMMUNICATIONS 2020.
  • Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

    Autores: Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J.
    Referencia: LANCET ONCOLOGY 2020.
  • SEOM clinical guidelines in early stage breast cancer (2018)

    Autores: Ayala de la Peña F., Andrés R., Garcia-Sáenz J., Manso L., Margelí M., Dalmau E., Pernas S., Prat A., Servitja S., Ciruelos E..
    Referencia: CLINICAL AND TRANSLATIONAL ONCOLOGY 2019.
  • A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

    Autores: Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R .
    Referencia: ANNALS OF ONCOLOGY.
  • Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

    Autores: Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A.
    Referencia: JOURNAL FOR IMMUNOTHERAPY OF CANCER 2019.
  • PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

    Autores: Conte, Pier Franco; Griguolo, Gaia; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba Ariela; Frassoldati, Antonio; Cavanna, Luigi; Musolino, Antonino; Giotta, Francesco; Rimanti, Anita; Garrone, Ornella; Galvan, Patricia; Maristany, Fara Braso; Orvieto, Enrico; Urso, Loredana; Maiorana, Antonino; Balduzzi, Sara; D'Amico, Roberto; Guarneri, Valentina; Prat, Aleix;.
    Referencia: JOURNAL OF CLINICAL ONCOLOGY 2019.
  • Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.

    Autores: Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A .
    Referencia: ANNALS OF ONCOLOGY 2018; 29(10):2121-2128.
  • Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.

    Autores: Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M, Prat A .
    Referencia: CANCER TREATMENT REVIEWS 2018.
  • Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials

    Autores: Laurberg T., Tramm T., Nielsen T., Alsner J., Nord S., Myhre S., Sørlie T., Leung S., Fan C., Perou C., Gelmon K., Overgaard J., Voduc D., Prat A., Cheang M.C.U..
    Referencia: ACTA ONCOLOGICA 2018.
  • HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial

    Autores: Llombart-Cussac, Antonio; Cortes, Javier; Pare, Laia; Galvan, Patricia; Bermejo, Begona; Martinez, Noelia; Vidal, Maria; Pernas, Sonia; Lopez, Rafael; Munoz, Montserrat; Nuciforo, Paolo; Morales, Serafin; Oliveira, Mafalda; de la Pena, Lorena; Pelaez, Alexandra; Prat, Aleix;.
    Referencia: LANCET ONCOLOGY 2017.

Proyectos destacados

  • Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

    Investigador/a principal: Aleix Prat Aparicio
    Financiador: FUNDACIÓ LA MARATÓ DE TV3
    Código: 201935-30-31-32
    Duración: 01/01/2020 - 01/01/2022
  • Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

    Investigador/a principal: Aleix Prat Aparicio
    Financiador: AECC, FUNDACIÓN CIENTÍFICA ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER
    Código: GCAEC19010PRAT
    Duración: 01/01/2020 - 31/12/2024
  • RESCUER. Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

    Investigador/a principal: Aleix Prat Aparicio
    Financiador: HORIZON 2020 RESEARCH AND INNOVATION FRAMEWORK PROGRAMME
    Código: H2020-SC1-BHC-2018-2020
    Duración: 01/01/2020 - 31/12/2025
  • Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

    Investigador/a principal: Aleix Prat Aparicio
    Financiador: INSTITUTO CARLOS III (FIS, FONDO DE INVESTIGACION SANITARIA)
    Código: PI19/01846
    Duración: 01/01/2020 - 31/12/2022
  • A European Cancer Image Platform Linked to Biological and Health

    Investigador/a principal: Aleix Prat Aparicio
    Financiador: HORIZON 2020 FRAMEWORK PROGRAMME
    Código: 952103 — EuCanImage
    Duración: 01/01/2020 - 31/12/2022